Table 1.
Baseline characteristics of patients stratified by tertiles of LnSII
| Variables# | Tertile categories of LnSII | P value | ||
|---|---|---|---|---|
| T1 (n = 174) | T2 (n = 174) | T3 (n = 175) | ||
| Demographics | ||||
| Age (years) | 66.25 ± 9.34 | 65.86 ± 9.97 | 64.99 ± 11.56 | 0.511 |
| Male, n (%) | 125 (71.84%) | 132 (75.86%) | 140 (80.00%) | 0.204 |
| BMI (kg/m2) | 24.19 ± 3.03 | 24.14 ± 3.30 | 24.32 ± 2.65 | 0.881 |
| Current smoking, n (%) | 75 (44.12%) | 73 (43.45%) | 92 (53.18%) | 0.131 |
| Medical history | ||||
| Hypertension, n (%) | 20 (11.49%) | 33 (18.97%) | 44 (25.14%) | 0.005 |
| Hyperlipidemia, n (%) | 4 (2.30%) | 8 (4.60%) | 12 (6.86%) | 0.126 |
| Diabetes, n (%) | 53 (30.46%) | 39 (22.41%) | 56 (32.00%) | 0.103 |
| Chronic kidney disease, n (%) | 3 (1.72%) | 7 (4.02%) | 5 (2.86%) | 0.438 |
| Laboratory tests | ||||
| eGFR (ml/min/1.73m2) | 80.28 ± 18.08 | 77.85 ± 23.56 | 78.97 ± 22.13 | 0.570 |
| FPG (mmol/L) | 5.97 ± 2.21 | 5.91 ± 2.12 | 7.09 ± 3.31 | < 0.001 |
| HbA1c (%) | 6.19 ± 1.22 | 6.27 ± 1.25 | 6.40 ± 1.33 | 0.504 |
| SUA (umol/L) | 367.85 ± 95.11 | 377.40 ± 101.69 | 385.40 ± 121.05 | 0.308 |
| Albumin, serum (g/L) | 38.69 ± 3.47 | 37.85 ± 3.39 | 37.19 ± 3.55 | < 0.001 |
| TC (mmol/L) | 4.01 ± 0.87 | 4.38 ± 1.02 | 4.69 ± 1.00 | < 0.001 |
| Triglycerides (mmol/L) | 1.50 ± 0.74 | 1.67 ± 1.12 | 1.84 ± 1.11 | 0.010 |
| HDL-C (mmol/L) | 1.05 ± 0.29 | 1.03 ± 0.23 | 1.00 ± 0.24 | 0.250 |
| LDL-C (mmol/L) | 2.33 ± 0.69 | 2.67 ± 0.89 | 2.93 ± 0.83 | < 0.001 |
| Homocysteine (umol/L) | 14.29 ± 5.36 | 15.27 ± 7.08 | 16.23 ± 8.07 | 0.040 |
| Angiographic findings | ||||
| Chronic total occlusions, n (%) | 23 (13.22%) | 19 (10.92%) | 26 (14.86%) | 0.547 |
| Number of stent (/patients) | 2 (1, 2) | 2 (1, 2) | 1 (1, 2) | 0.095 |
| Length of stents (mm/patients) | 26.88 ± 6.30 | 26.81 ± 6.36 | 27.64 ± 5.98 | 0.381 |
| Minimal stent diameter (mm) | 3.05 ± 0.44 | 3.01 ± 0.49 | 3.02 ± 0.43 | 0.713 |
| Medications at discharge | ||||
| Aspirin, n (%) | 174 (100.00%) | 174 (100.00%) | 175 (100.00%) | > 0.99 |
| Clopidogrel/ticagrelor, n (%) | 174 (100.00%) | 174 (100.00%) | 175 (100.00%) | > 0.99 |
| Statin, n (%) | 174 (100.00%) | 172 (98.85%) | 173 (98.86%) | 0.366 |
| β-block, n (%) | 151 (86.78%) | 163 (93.68%) | 155 (88.57%) | 0.090 |
| ACEI/ARB, n (%) | 115 (66.09%) | 114 (65.52%) | 130 (74.29%) | 0.142 |
| Oral hypoglycemic drugs, n (%) | 42 (24.14%) | 26 (14.94%) | 50 (28.57%) | 0.008 |
SII systemic immune-inflammation index, BMI body mass index, eGFR estimated glomerular filtration rate, FPG fasting plasma glucose, HbA1c hemoglobin A1c, TC total cholesterol, HDL-C high-density lipoprotein-C, LDL-C low-density lipoprotein-C, SUA serum uric acid, ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor blocker
#Data are shown as mean ± SD, median (IQR), or n (%)